Adverse event reporting signals for SGLT-2 inhibitor-metformin combination therapy: a disproportionality analysis of the FAERS database.

Zhou W, Xia Y, Li J, Wang F

Open source

DOI
10.3389/fendo.2026.1917352
Published
2026
Container
Frontiers in endocrinology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fendo.2026.1917352,
  title = {Adverse event reporting signals for SGLT-2 inhibitor-metformin combination therapy: a disproportionality analysis of the FAERS database.},
  author = {Zhou W and Xia Y and Li J and Wang F},
  year = {2026},
  journal = {Frontiers in endocrinology},
  doi = {10.3389/fendo.2026.1917352},
  url = {https://doi.org/10.3389/fendo.2026.1917352}
}

RIS

TY  - JOUR
TI  - Adverse event reporting signals for SGLT-2 inhibitor-metformin combination therapy: a disproportionality analysis of the FAERS database.
AU  - Zhou W
AU  - Xia Y
AU  - Li J
AU  - Wang F
PY  - 2026
JO  - Frontiers in endocrinology
DO  - 10.3389/fendo.2026.1917352
UR  - https://doi.org/10.3389/fendo.2026.1917352
ER  - 

APA

W, Z., Y, X., J, L., & F, W. (2026). Adverse event reporting signals for SGLT-2 inhibitor-metformin combination therapy: a disproportionality analysis of the FAERS database.. Frontiers in endocrinology. https://doi.org/10.3389/fendo.2026.1917352

Source records